When we look at a term sheet, we see a single piece of an overall business strategy.
Our goal is to design a transaction, not just to monetize IP, but also to drive the growth of your entire business. We can help you in the following ways:
Start-up
License core technologies and obtain venture financing
License, Collaboration and Option Agreement to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M per product plus royalties
FogPharma raises Series C equity funding led by venBio Partners, Cormorant Asset Management, Farallon Capital Mgmt., Invus, funds/accounts advised by T. Rowe Price, HBM Healthcare Investments, Casdin Capital and PagsGroup, w/participation from investors GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital
TB Alliance - GlaxoSmithKline Investigacion Y Desarollo, S.L.
Research and Development Collaboration Agreement
Amended and Restatement of Research and Development Collaboration Agreement with GSK to identify and advance novel chemical entities for the potential treatment of TB as well as non-tuberculosis mycobacterial infections
Assignment, Amendment and Early Option Exercise Agreements
Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms
Research and Option Agreement to Acquire Exclusive License
Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program.
Exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP) (including up to $535 million in potential development, regulatory and sales-based milestones and other payments, plus tiered percentage royalties)
Lundbeckfond’s sale to New Enterprise Associates 14, LP of certain royalty rights receivable in connection with the merger of Vtesse Inc. with and into a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.—Vir Biotechnology, Inc.
Collaboration and License Agreement
Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases
Sojournix, Inc.
Series C Financing
Sojournix, Inc. raises Series C equity funding from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors
License, Collaboration and Option Agreement to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M per product plus royalties
FogPharma raises Series C equity funding led by venBio Partners, Cormorant Asset Management, Farallon Capital Mgmt., Invus, funds/accounts advised by T. Rowe Price, HBM Healthcare Investments, Casdin Capital and PagsGroup, w/participation from investors GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital
TB Alliance - GlaxoSmithKline Investigacion Y Desarollo, S.L.
Research and Development Collaboration Agreement
Amended and Restatement of Research and Development Collaboration Agreement with GSK to identify and advance novel chemical entities for the potential treatment of TB as well as non-tuberculosis mycobacterial infections
Assignment, Amendment and Early Option Exercise Agreements
Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms
Research and Option Agreement to Acquire Exclusive License
Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program.
